Price (delayed)
$23.61
Market cap
$2.94B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5
Enterprise value
$3.35B
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger
There are no recent dividends present for ARWR.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.